RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. Its products includes RCT-01, RCS-01, and RCH-01. The company was founded by Kevin McElwee and Rolf Hoffmann on April 24, 1967 and is headquartered in Vancouver, Canada.